The most common sustained clinical tachyarrhythmia, atrial fibrillation (AF), is characterized in part by its self-perpetuating nature. AF self-perpetuation is caused by complex changes in cardiomyocyte electrical and contractile function resulting from atrial activation-rate increases. AF treatment approaches that focus on cardiac electrical properties have limited effectiveness and significant potential complications. There is, therefore, increased interest in therapeutic approaches that target mechanisms, such as electrical remodeling, that contribute to the AF substrate.

Induction of the heat-shock response provides cytoprotective effects that may be beneficial for a variety of acute diseases. Because such action depends on the timely induction of heat-shock proteins (HSPs), drugs that boost endogenous heat-shock responses may be of particular interest. Atrial HSPs are increased in clinical AF, and this response correlates with reduced AF perpetuation. Here, we assess the role of HSP induction in preventing the effects of AF-related atrial tachycardia remodeling in an in vitro HL-1 myocyte model system that is appropriate for genetic manipulation (transient transfection) and in tachypaced isolated canine atrial cardiomyocytes. Because HSP induction prevented electrical and contractile remodeling in vitro, we extended our study to a clinically relevant in vivo model to determine whether HSP induction by an orally administered (co)inducer, geranylgeranylace-tone (GGA), protects against AF.

Materials and Methods

**HL-1 Cell Culture Conditions, Transfections, and Constructs**

HL-1 cells were obtained from William Claycomb (Louisiana State University, New Orleans) and cultured as previously described. Transient transfection was performed with Lipofectamine (Life Technologies). pHSP70-wt encodes human HSP70 and pHSP27-wt encodes human HSP27, both under control of cytomegalovirus.
promoter (Clontech). For phosphorylation studies, we used the phosphorylation-deficient mutant HSP27-AAA, in which the 3 known phosphorylation sites (Ser15, Ser78, and Ser82) in HSP27-wt are mutated to alanine, or a phosphorylation-mimicking mutant HSP27-DDD, with these serine residues replaced by negatively charged aspartates.15 Empty pSP64 vector was used as a control. Myocytes were cotransfected with CD-8 cDNA and successfully transfected myocytes selected with anti-CD8 Dynabeads (Dynal).

Pacing and Induction of HSP Expression
HL-1 myocytes cultured on coverslips showed spontaneous contraction at \( \approx \)0.5 Hz. The cells were tachypaced in C-Dish100 culture dishes with a C-Pace100 pacer (IonOptix). HL-1 myocytes were stimulated at 3 Hz with square-wave 5-ms pulses. Results in paced cells were compared with nonpaced cells studied in parallel. We required capture efficiency of >90% cells (microscopic examination of cell shortening [CS]) throughout stimulation. HSP expression was induced: (1) by subjecting cells to modest heat shock (43°C×15 minutes) followed by overnight incubation at 37°C; (2) by incubation with GGA 4 hours before and during pacing; or (3) by transfection of pHSPT70-wt, pHSPT27-wt, or pHSPT-AAA/DDD 24 hours before in vitro study.

Short Interfering RNA
The pSUPER-RNAi system13 was used to develop mouse HSP27 short interference RNA (siRNA) (all from 5’ to 3’; forward, GATCCCC GACCAAGGATGCCGTTTCAAGA CAC CGCCATCTCTGGT TTTTTA; reverse, AGCTTAAAAA GACAAGATGGCGTTG TCTCTTGAACACCGC CGTCTTTGGT GGG); HSP27 siRNAII (forward, GATCCCC GTTGGCGTGGTGGAGATC TTCAAGAGA GATCTCCACGC CATCCTTGGTC GGG); and mock siRNA (forward, GATCCCC GAACTGGTTGAGATC TTCAAGAGA GATCTCCACGC CATCCTTGGTC GGG). Myocytes were transfected with siRNA constructs for 3 days. Four hours before tachypacing, cells were incubated with GGA and Ca\(^{2+}\) transient amplitude (CaT) and CS were measured. To test siRNA efficiency, HEK293 cells were transfected with mouse HSP27-GFP construct and siRNA, siRNAII, or mock siRNA.

Calcium Transient and CS Measurements
These measurements were performed as described previously.14,15 The CaT amplitude (Δ[Ca\(^{2+}\)]mem) was the difference between diastolic and systolic values. Mean amplitude for each experimental condition was based on 10 consecutive CaTs in 50 to 100 myocytes. CS (maximum minus minimum cell length) was measured with a video edge detector (Crescent Electronics) coupled to a charge-coupled device camera. The contraction signal was digitized at 200 Hz (TL-1 A/D Converter, Axon). Edge-detection cursors were positioned at both ends of myocytes to measure whole-cell shortening. CS was measured relative to diastolic cell length based on the average of 10 consecutive beats.

Single Canine Atrial Cardiomyocyte Isolation and GGA Treatment
Single canine left atrial cells were isolated by previously developed methods.16 Hearts were excised via left thoracotomy under pentobarbital (30 mg/kg IV) anesthesia and immersed in Tyrode’s solution. All dissection and perfusion solutions were equilibrated with 4% CO\(_2\)-enriched atmosphere. After 4 hours, dead and unattached myocytes were removed and fresh medium was added. Pacing was performed for 24 hours with square-wave, 5-ms pulses. For each set of experiments, parallel studies were performed with cells cultured in the presence of 1-Hz (P1) and 3-Hz (P3) pacing and no pacing (P0 cells). After 24 hours, cells were superfused at 3 mL/min with extracellular solution (36±1°C) to record action potentials (APs) and I\(_{Ca-L}\).

Cell Electrophysiology Recordings
The whole-cell patch-clamp technique was used to record currents in voltage-clamp mode and APs in current-clamp mode. Borosilicate glass electrodes (1.0-mm outer diameter) filled with pipette solution were connected to a patch-clamp amplifier (Axopatch 200A, Axon). Electrodes had tip resistances of 2 to 5 MΩ, with perforated-patch technique used to record APs and tight-seal patch-clamp to record I\(_{Ca-L}\). Pipette tips for perforated-patch studies were filled with nystatin-containing (60 μg/mL) intracellular solution. Currents are expressed as densities (pA/pF).

In Vivo Model
Animal-handling procedures followed guidelines of the National Institutes of Health and were approved by the Animal Research Ethics Committee of the Montreal Heart Institute. Fifteen mongrel dogs (28 to 38 kg) were anesthetized with ketamine (5.3 mg/kg IV), diazepam (0.25 mg/kg IV), and halothane (1.5%). Unipolar pacing leads were inserted into the right ventricular apex and right atrial (RA) appendage under fluoroscopic guidance and were connected to pacemakers (Vitatron) in subcutaneous pockets in the neck. Atrioventricular block was created by radiofrequency catheter ablation to avoid excessively rapid ventricular responses during atrial tachypacing. The right ventricular demand pacemaker was programmed to 80 bpm. After 24-hour recovery, 7-day atrial tachypacing at 400 bpm was instituted.

Results in 5 atrial tachypaced dogs with GGA treatment were compared with 5 tachypaced dogs without GGA and 5 nonpaced control dogs. GGA was given orally (120 mg/kg per day), starting 3 days before and continuing throughout atrial tachypacing. At the end of the preparation period, dogs were anesthetized with ketamine (5.3 mg/kg IV), diazepam (0.25 mg/kg IV), and halothane (1.5%). Unipolar pacing leads were inserted into the right ventricular apex and right atrial (RA) appendage under fluoroscopic guidance and were connected to pacemakers (Vitatron) in subcutaneous pockets in the neck. Atrioventricular block was created by radiofrequency catheter ablation to avoid excessively rapid ventricular responses during atrial tachypacing. The right ventricular demand pacemaker was programmed to 80 bpm. After 24-hour recovery, 7-day atrial tachypacing at 400 bpm was instituted.
minutes was terminated by direct-current electrical cardioversion. A 20-minute rest period was allowed before continuing measurements. If prolonged AF was induced twice, no further AF induction was performed. Atrial ERPs were measured at multiple basic cycle lengths in the RA appendage and at a basic cycle length of 300 ms at 7 additional sites: LA appendage, RA and LA posterior wall, RA and LA inferior wall, RA and LA Bachmann’s bundle. AF vulnerability was the percentage of atrial sites at which AF was induced by single extrastimuli. Hearts were preserved in formalin for analysis of cell death (hematoxylin/phloxine/saffron stain) and fibrosis (Masson’s Trichrome).

**Western Blot Analysis**

Frozen RAs and LAs were used for protein isolation. For protein isolation from HL-1 myocytes, cells were lysed by adding SDS-PAGE sample buffer followed by sonication before separation on 10% polyacrylamide–sodium dodecyl sulfate gels (10^5 cells/slot). After transfer to nitrocellulose membranes (Stratagene), membranes were incubated with primary antibodies against GAPDH (Affinity Reagents), rodent HSP27 (SPA801), human HSP27 (SPA800), or HSP70 (SPA810; all from StressGen). Horseradish peroxidase–conjugated anti-mouse or anti-rabbit IgG (Santa Cruz Biotechnology) was used as secondary antibody. Signals were detected by ECL detection (Amersham) and quantified by densitometry.

**Data Analysis**

Data are presented as mean ± SEM. Multiple-group comparisons were obtained by ANOVA with Bonferroni corrected post hoc t tests. All data fulfilled criteria for parametric analysis, except AF duration, which was normalized by logarithmic transformation. A 2-tailed P<0.05 was considered statistically significant.

**Results**

**Effect of HSP Induction on Tachypaced HL-1 Myocytes**

We first examined the effect of HSP induction in cultured HL-1 cells, an in vitro model of atrial tachycardia remodeling. HSP expression was increased by preexposure to GGA or heat shock (Figure 1). Cell tachypacing reduced CaT and contractile function, effects prevented by HSP induction (Figure 2A and 2B). To assess the efficacy of individual HSPs, HL-1 myocytes were transiently transfected with human wild-type (wt) HSP70 or HSP27 before pacing. Transfection with HSP27-wt prevented tachycardia-induced CaT (Figure 2A and 2C) and CS (Figure 2A and 2C) depression, whereas HSP70-wt was ineffective (Figure 2C). In addition, we synthesized short hairpin RNAs that act as siRNA-like molecules to specifically knock down HSP27 expression in GGA-treated myocytes and compared their response with cells transfected with mock siRNA (containing multiple mismatches to murine HSP27 sequence). Two HSP27 siRNA molecules (directed at different parts of the HSP27 sequence) were used: either prevented GGA-mediated protection against CaT and CS reduction (Figure 3). The results in Figures 2C and 3 indicate that HSP27 is sufficient and required for GGA-induced protection. Recent studies in smooth muscle cells demonstrated that protective effects of HSP27 on contractile function depend on its phosphorylation status. Therefore, HL-1 myocytes were transfected with either phosphorylation-deficient HSP27 (HSP-AAA) or a phosphorylation-mimicking mutant (HSP27-DDD). Only the phosphorylation-mimicking mutant prevented reductions in CaT and CS (Figure 2C), showing that the protective actions of HSP27 require its phosphorylation.

**In Vitro Effect of GGA Treatment on Electrical Remodeling in Dog Atrial Myocytes**

Figure 4A shows typical I_{Ca,L} recordings on 200-ms depolarizing pulses from -50 mV to +10 mV. Mean data at all test potentials for each group are provided in Figure 4B. In the absence of GGA, tachypacing reduced I_{Ca,L} amplitude (Figure 4, left panels). For example, I_{Ca,L} density at +10 mV averaged 1.9 ± 0.4 pA/pF in 3-Hz paced (P3) cells (n=13), 40% of the value of 4.8 ± 1.6 pA/pF in 1-Hz paced (P1) cells (n=9, P<0.001). There were no appreciable differences between P1 and nonpaced (P0) cells. GGA prevented tachypacing-induced reductions in I_{Ca,L}, with changes being greatly attenuated at 10 μmol/L and virtually abolished at 100 μmol/L.
APs were recorded at multiple frequencies after 24-hour pacing at 0, 1, or 3 Hz in P0, P1, and P3 cells. Resting membrane potential was not altered by rapid pacing, averaging $-71.4 \pm 1.5$ mV ($n=11$) in P0 cells compared with $-73.8 \pm 1.8$ mV ($n=16$) in P1 cells and $-73.8 \pm 1.1$ mV ($n=19$) in P3 cells ($P=NS$). APs recorded during 1-Hz stimulation from P1 and P3 atrial cardiomyocytes are illustrated in Figure 5 (left panels). Results were not significantly different in P0 versus P1 cells; therefore, for simplicity, only the P1 and P3 data are shown. Mean AP duration (APD) data at 90% repolarization (APD$_{90}$) are shown as a function of recording frequency in the right panels. Tachypacing reduced APD and attenuated APD rate dependence, characteristics of in vivo atrial tachycardia remodeling.1,16,17 GGA treatment prevented tachypacing-induced APD changes.

To assess possible direct electrophysiological effects of GGA, we recorded $I_{CaL}$ and AP properties before and after drug superfusion. As shown in Figures I and II in the online data supplement, available at http://circres.ahajournals.org, GGA had no statistically significant direct effects at concentrations that prevented tachypacing-induced remodeling of $I_{CaL}$ and APD.

### In Vivo Effect of HSP Induction

Having demonstrated that HSP induction in an in vitro atrial-derived cell model protects against tachycardia-induced remodeling and GGA administration in isolated dog atrial myocytes prevents electrical remodeling, we studied in vivo applicability. Tachypacing alone did not affect HSP expression, but GGA treatment significantly increased HSP expression in both RA and LA (Figure 6). There were no significant differences among hemodynamic variables, but GGA-treated dogs were slightly larger than the other groups (Table). Results of electrophysiological studies after 7 days of atrial tachypacing in GGA-treated and nontreated dogs are shown in Figure 7, along with results in nonpaced control dogs. Atrial tachypacing in the absence of GGA produced the changes typical of atrial tachycardia remodeling, reducing atrial ERP and ERP rate adaptation (Figure 7A). The atrial tachypacing–induced ERP decreases were attenuated by GGA therapy. Atrial tachypacing without GGA reduced ERP in a statistically significant fashion at most atrial sites (Figure 7B). Atrial tachypacing–induced ERP decreases were regionally variable, as previously described,23 with the largest changes occurring in the RA inferior wall, posterior wall, and appendage, as well as the LA appendage. GGA significantly attenuated atrial tachypacing effects on ERP in the RA appendage, atria, posterior wall, inferior wall, and Bachmann’s bundle. The mean duration of induced AF was increased by tachycardia remodeling from $30$ seconds to $\approx 15$ minutes (Figure 7C), and atrial vulnerability to AF induction by premature extrastimuli increased from $\approx 10\%$ to
We considered the possibility that the prevention of tachypacing-induced I_{CaL} downregulation and APD abbreviation might come at the expense of impaired cellular viability. Therefore, we compared atrial cell death and fibrous tissue content in atrial tissue samples taken after euthanasia of control, atrial tachypacing nontreated, and atrial tachypacing GGA-treated dogs. The results (supplemental Figure III) show no negative impact of GGA therapy. We also analyzed cell-death rate in 24 hours in vitro tachypaced cardiomyocytes. Tachypacing in the absence of GGA reduced cell viability, whereas GGA eliminated this effect (supplemental Table I), suggesting that HSP induction has, if anything, favorable effects on tachypaced cardiomyocyte stability.

**Discussion**

It is well known that AF promotes its own maintenance by causing tachycardia-induced remodeling. We evaluated the effect of HSP induction in an in vitro tachypaced atrial cell line (HL-1) model of AF-related tachycardia remodeling and in tachypaced isolated atrial myocytes from dogs, as well as in vivo on AF promotion by atrial tachycardia–induced remodeling in dogs.

HSP induction by heat shock or GGA protected HL-1 myocytes against suppression of cellular Ca^{2+} release and contractility resulting from tachypacing. Protective effects were also seen on transfection with HSP27 and a phosphorylation-mimicking HSP27 mutant, but not by HSP70 or a nonphosphorylatable HSP27 mutant construct. Knockdown of HSP27 with short-hairpin forming siRNA prevented GGA-mediated protection. These results indicate that HSP induction protects against tachypacing effects on HL-1 cells, that HSP27 (but not HSP70) is sufficient to reproduce this protective effect, that knockdown of HSP27 prevents protection because of GGA-induced HSP induction, and that HSP27 must be in a phosphorylatable form for protection to occur.

To translate our results to more physiologically relevant systems, we developed an isolated atrial cardiomyocyte model and found both that it reproduced in vivo consequences of atrial tachycardia remodeling and that it demonstrated protective effects with GGA. Finally, we found that protective effects with GGA were also manifest in vivo.

**GGA Induces HSP Expression**

GGA is a nontoxic acyclic isoprenoid compound with a retinoid skeleton that induces HSP synthesis in various tissues, including gastric mucosa, intestine, liver, myocardium, retina, and central nervous system.6,7,24 GGA induces HSP expression through activation of the heat shock transcription factor HSF1.24,25 Oral administration of GGA rapidly upregulates HSP expression in response to a variety of stresses, although this effect is weaker under nonstress conditions.26 The protective effect of GGA-induced HSP expression on atrial remodeling that we observed in in vitro and in vivo models of atrial tachycardia–induced AF promotion suggests that HSP induction might have potential value for clinical AF.

**Relationship to Previous Observations Regarding Drug Effects on Atrial Tachycardia–Induced Remodeling**

Pharmacological approaches to prevent atrial remodeling are being studied, with the hope that they might be useful in treating AF. L-type Ca^{2+} channel blockers, a Na^{+}/H^{+} exchange inhibitor and an angiotensin-converting enzyme inhibitor, are ineffective in preventing remodeling caused by >24 hours of atrial tachycardia.27 Drugs with T-type Ca^{2+} channel blocking action, such as mibebradil28 and amiodarone,29 prevent atrial tachycardia remodeling, although their precise mechanism of action is unclear. Interventions with antiinflammatory and/or antioxidant actions, such as glu-
cocorticoids\textsuperscript{17} and statins,\textsuperscript{18} prevent atrial remodeling and may have some efficacy in clinical AF.\textsuperscript{30,31} Our results suggest that HSP induction is a novel antiremodeling intervention.

**HSPs, Cardioprotection, and Arrhythmias**

HSPs, also known as “stress proteins,” are induced by a variety of stressors and show significant cardioprotective actions.\textsuperscript{32} HSP27 (which in various species has molecular

\begin{itemize}
  \item \textsuperscript{30} \& \textsuperscript{31}
\end{itemize}

\begin{itemize}
  \item \textsuperscript{32}
\end{itemize}

- **Figure 4.** GGA prevents tachypacing-induced $I_{calc}$ reductions in isolated canine atrial cardiomyocytes. A, Recordings of $I_{calc}$ in cardiomyocytes paced in vitro at 0, 1, or 3 Hz (P0, P1, P3, respectively) without or with 10, 100, or 1000 $\mu$mol/L GGA. Arrows point to current peak of each recording. B, Mean±SEM $I_{calc}$ density as a function of test potential during 200-ms depolarizing pulses (0.1 Hz) from $-50$ mV. *P<0.05, **P<0.01, ***P<0.001 vs 1-Hz paced cardiomyocytes.

- **Figure 5.** GGA prevents tachypacing-induced APD shortening in isolated canine atrial cardiomyocytes. Left, AP recordings from cardiomyocytes paced for 24 hours at 1 or 3 Hz (P1, P3, respectively) without (A) or with (B) 100 $\mu$mol/L GGA. Right, Mean±SEM APD in P1 and P3 cardiomyocytes paced in the absence (A) and presence (B) of 100 $\mu$mol/L GGA. *P<0.05, **P<0.01 vs P1 cardiomyocytes.
an important role in heat-shock–induced prevention of doxorubicin cardiotoxicity.\textsuperscript{38} Phosphorylated HSP isoforms stabilize actin filaments and prevent their remodeling.\textsuperscript{38} Actin filament disruption impairs L-type Ca\textsuperscript{2+} channel function\textsuperscript{10}, therefore, the actin-stabilizing effect of phosphorylated HSP27 may contribute to preventing atrial tachycardia–induced $I_{\text{CaL}}$ decreases and associated APD/ERP reductions. HSPs have potentially significant antioxidant properties,\textsuperscript{32} and there is evidence that oxidant stress contributes to the pathophysiology of AF\textsuperscript{40–42} and that compounds with antioxidant properties protect against atrial remodeling.\textsuperscript{17,18} Thus, prevention of oxidant stress–induced injury is another potential contributor to HSP-mediated protection against tachycardia remodeling and associated AF promotion.

**Novelty and Potential Significance**

HSPs have been shown to be cardioprotective in a variety of paradigms.\textsuperscript{32} Our study is the first to show that HSP induction protects against AF in an in vivo model and to probe potential underlying mechanisms in isolated atrial cardiomyocyte and atrial cell line models. Our results are relevant to understanding the molecular determinants of atrial remodeling and potentially to the development of new therapeutic approaches. The atrial-derived cell line model permitted molecular manipulation that demonstrated the importance of HSP27 and of its phosphorylation in HSP-mediated protection. The in vitro paced canine cardiomyocyte model provided an important bridge between the atrial-derived cell line work and in vivo observations. This is, to our knowledge, the first time that an in vitro tachypaced model of adult large-animal atrial cardiomyocytes has been used to probe tachycardia remodeling. The qualitative similarity of the ionic-current and AP changes we observed in the in vitro tachypaced atrial cardiomyocytes to previously described changes in atrial cardiomyocytes from in vivo tachypaced dogs\textsuperscript{33} ($I_{\text{CaL}}$ downregulation, APD abbreviation and loss of APD rate adaptation) make the in vitro model potentially interesting for further studies of the pathophysiology of tachycardia remodeling.

**Potential Limitations**

We studied CaTs and CS as indices of remodeling in HL-1 cells, because these parameters are affected by atrial tachycardia remodeling\textsuperscript{14,15} and can be monitored in intact cells, avoiding the effects of dialysis with tight-seal patch clamp on cellular function. Caution must be used in extrapolating from the HL-1 myocyte model, because of its origin (mouse atrial tumor cells) and possible phenotypic drift. The in vitro canine cardiomyocyte model is therefore an important complement that allowed us to investigate $I_{\text{CaL}}$ and APD, believed to be of fundamental importance to refractoriness changes involved in AF promotion. However, our studies of molecular bases of HSP protection (showing the crucial role of phosphorylated HSP27)$^\text{a}$ were performed only in HL-1 myocytes and should be interpreted in this light. This work raises additional issues, such as the precise intracellular basis for HSP-induced protection, the mechanisms by which $I_{\text{CaL}}$ reductions may be affected by phosphorylated HSP27, and the effects of HSPs on other ionic currents (eg, inward-

**General Properties at Open-Chest Study**

<table>
<thead>
<tr>
<th></th>
<th>NP</th>
<th>ATP</th>
<th>ATP + GGA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight, kg</td>
<td>33 ± 2</td>
<td>30 ± 1</td>
<td>36 ± 1*</td>
</tr>
<tr>
<td>Systolic BP, mm Hg</td>
<td>115 ± 8</td>
<td>123 ± 18</td>
<td>124 ± 3</td>
</tr>
<tr>
<td>Diastolic BP, mm Hg</td>
<td>63 ± 6</td>
<td>61 ± 10</td>
<td>63 ± 5</td>
</tr>
<tr>
<td>LVSP, mm Hg</td>
<td>116 ± 9</td>
<td>124 ± 16</td>
<td>125 ± 3</td>
</tr>
<tr>
<td>LVEDP, mm Hg</td>
<td>6 ± 1</td>
<td>6 ± 1</td>
<td>6 ± 1</td>
</tr>
<tr>
<td>LAP, mm Hg</td>
<td>5 ± 1</td>
<td>6 ± 2</td>
<td>5 ± 1</td>
</tr>
</tbody>
</table>

NP indicates nonpaced control; ATP, atrial tachypacing only; ATP + GGA, atrial tachypacing with GGA treatment; BP, blood pressure; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; LAP, LA pressure. *P<0.05 vs atrial tachypacing only.
rectifier K⁺ currents) that participate in atrial tachycardia–induced AF promotion. However, the extensive additional experiments needed to address these issues go beyond the context of the present study. GGA-treated dogs were slightly larger than the other groups (Table). This difference should, if anything, have favored AF maintenance in atrial tachypacing GGA-treated dogs and should have decreased our chances of showing GGA-induced protection.

Acknowledgments
Nathalie L’Heureux, Chantal Maitais, and Chantal St-Cyr provided expert technical assistance; France Thériault helped greatly with manuscript preparation and submission; Jurrie Hageman helped to prepare the siRNA constructs; and Eisai Pharmaceuticals, Japan, generously provided GGA.

Sources of Funding
We thank the Canadian Institutes for Health Research, the Quebec Heart and Stroke Foundation, the Dutch Organization for Scientific Research (NWO program grant 916.46.043), Interuniversity Cardiology Institute of The Netherlands and European Union (grant QLK3-CT-2000-00720) for financial support.

Disclosures
None.

References


Induction of Heat Shock Response Protects the Heart Against Atrial Fibrillation

Bianca J. J. M. Brundel, Akiko Shirosita-Takeshita, XiaoYan Qi, Yung-Hsin Yeh, Denis Chartier, Isabelle C. van Gelder, Robert H. Henning, Harm H. Kampinga and Stanley Nattel

Circ Res. 2006;99:1394-1402; originally published online November 16, 2006;
doi: 10.1161/01.RES.0000252323.83137.fe

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/99/12/1394

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2006/11/16/01.RES.0000252323.83137.fe.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
Online Table 1

Percentage of live versus dead canine atrial cardiomyocytes after 24 hours of in vitro pacing at the frequencies shown

<table>
<thead>
<tr>
<th></th>
<th>Live cells</th>
<th>Dead cells</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTROL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 0 Hz</td>
<td>55±4%</td>
<td>45±4%</td>
</tr>
<tr>
<td>P 1 Hz</td>
<td>53±6%</td>
<td>47±6%</td>
</tr>
<tr>
<td>P 3 Hz</td>
<td>30±4%*</td>
<td>70±4%</td>
</tr>
<tr>
<td><strong>GGA 100 µM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 0 Hz</td>
<td>47±5%</td>
<td>53±5%</td>
</tr>
<tr>
<td>P 1 Hz</td>
<td>47±6%</td>
<td>53±6%</td>
</tr>
<tr>
<td>P 3 Hz</td>
<td>45±4%</td>
<td>55±4%</td>
</tr>
</tbody>
</table>

*P<0.05 vs P 0 and P 1 Hz cells.
Online Figure Legends

**Online Figure 1.** Direct effects of GGA (100 µmol/L, left; 1 mmol/L, right) on $I_{CaL}$ in canine atrial cardiomyocytes. Top: Typical recordings before and after GGA in individual cells; Bottom: mean data. Neither concentration significantly reduced $I_{CaL}$.

**Online Figure 2.** Direct effects of GGA on AP properties at a concentration (100 µmol/L) that fully prevented tachypacing-induced APD alterations. Top: Recordings before and after GGA in one cell. Bottom: Mean AP properties in absence and presence of GGA.

**Online Figure 3.** Analyses of atrial cell-death and fibrous tissue content. Left atrial samples were removed at the end of in vivo studies and immersed in 10%-neutral buffered formalin for >24 hours. Microscopic images of Masson’s trichrome-stained sections at 400× magnification were digitized (Scion Image Software) and analyzed with Sigmascan 4.0 (Jandel Scientific). Connective tissue content was quantified as a percentage of surface area, excluding blood vessels. To analyze cell-death, sections were stained with hematoxylin-phloxin-safran (HPS). Dead (acidophilic) and viable cells were counted in 5-10 transverse-section fields at 400×. **A.** Typical HPS sections from each group. **B.** Typical Masson’s Trichrome sections from each group. **C.** Mean±SEM dead-cell counts. **D.** Mean±SEM fibrous tissue contents.
Online Figure 1
Online Figure 2

GGA 100 μM (n=8) 147 ± 20
CTL (n=8) -79 ± 2 124 ± 8 81± 24 147 ± 20

GGA 100 μM (n=8) -77 ± 2 118 ± 4 80± 15 144 ± 14
Online Figure 3

A  
HPS stain

B  
Masson’s Trichrome stain

C  
Acidophilic cells (%)

D  
Fibrous Tissue (%)